GALDERMA

RESTYLANE®, the Original Stabilized Hyaluronic Acid Filler, Celebrates 25 Years of Unmatched Achievement

Retrieved on: 
Thursday, September 30, 2021
Other Consumer, Biotechnology, Other Health, Health, Cosmetics, Consumer, Retail, Other Science, Science, LYFT, Food, Partnership, Poster, CFDA, Achievement, Regulation of tobacco by the U.S. Food and Drug Administration, Hyaluronic acid, FDA, Patient, NMPA, Facial expression, Talarico, Bajaj Consumer Care, GAIN, Scottish Fold, MPH, National Medical Products Administration, Dermatology, Safety, Skin, Pharmaceutical industry, Cosmetics, Paint, Galderma, Galderma’s RESTYLANE portfolio, GALDERMA, GALDERMA’S RESTYLANE PORTFOLIO

The original non-animal stabilized hyaluronic acid filler restores, enhances and refreshes the youthful-looking appearance of the skin.

Key Points: 
  • The original non-animal stabilized hyaluronic acid filler restores, enhances and refreshes the youthful-looking appearance of the skin.
  • RESTYLANE is the original non-animal stabilized hyaluronic acid filler with over 25 years of achievement and over 50 million treatments worldwide.
  • High Patient Satisfaction of a Hyaluronic Acid FillerProducing Enduring Full-Facial Volume Restoration: An18-Month Open Multicenter Study.
  • Perioral rejuvenation with a range of customized hyaluronic acid fillers: efficacy and safety over six months with a specific focus on the lips.

Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology

Retrieved on: 
Thursday, September 23, 2021
Science, Other Science, Biotechnology, Medical Supplies, Health, Medical Devices, Cosmetics, Retail, Joint Medical Service (Germany), Partnership, Patient, Engineering, Ownership, Bajaj Consumer Care, Science, Silk, Dermatology, Hyaluronic acid, Time, Fibroin, Regeneration, Pharmaceutical industry, Sofregen’s Silk technology platform, Galderma, Sofregen Medical, SOFREGEN’S SILK TECHNOLOGY PLATFORM, GALDERMA, SOFREGEN MEDICAL

This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.

Key Points: 
  • This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.
  • At Galderma, were committed to advancing dermatology through constant innovation and joining forces with other industry pioneers.
  • This agreement highlights Sofregens dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space.
  • Galderma will also have an exclusive option to acquire Sofregens Silk Voice as well as assets associated with its aesthetics business.

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Retrieved on: 
Friday, June 11, 2021
Biotechnology, Pharmaceutical, Health, Medical devices, Drugs, Health, Botulism, Branches of biology, Plastic surgery, Botulinum toxin, Neurotoxins, Wrinkle, Galderma, Bont, Galderma, Alluzience® (liquid botulinum toxin type A), GALDERMA, ALLUZIENCE® (LIQUID BOTULINUM TOXIN TYPE A)

Galderma today announced that Alluzience has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe.

Key Points: 
  • Galderma today announced that Alluzience has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe.
  • Like many aspects of physical appearance, glabellar lines can have a significant impact on patients confidence and wellbeing.
  • Ive heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues.
  • Alluzience (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe.